Comparative Pharmacology
Head-to-head clinical analysis: GLUCOTROL versus GLYNASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUCOTROL versus GLYNASE.
GLUCOTROL vs GLYNASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptor 1 (SUR1) on ATP-sensitive potassium channels, causing depolarization and calcium influx. Also may increase peripheral insulin sensitivity.
Sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, leading to membrane depolarization and calcium influx.
Initial dose 5 mg orally once daily, increased by 2.5-5 mg increments weekly based on glycemic response; maximum 20 mg daily as single or divided doses (for doses >15 mg, administer in divided doses).
Initial dose 2.5-5 mg orally once daily with breakfast. Titrate by 2.5-5 mg weekly. Maximum dose 20 mg daily. Divided doses twice daily may be used for doses >10 mg.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours (mean 3.4 hours) in normal subjects; extended up to 8-12 hours in elderly or hepatic impairment due to reduced clearance.
Terminal elimination half-life: 10-16 hours; clinical context: correlates with duration of glucose-lowering effect, prolonged in renal impairment.
Primarily renal: ~80% as metabolites (mainly 4-trans-hydroxyglipizide and 3-cis-hydroxyglipizide) and ~10% unchanged; fecal: ~10%.
Renal: approximately 50% as metabolites and unchanged drug; fecal/biliary: minor (less than 5% as unchanged drug).
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic